Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
(RTTNews) - Verastem Oncology (VSTM) said it has exercised early the option to license from GenFleet Therapeutics VS-7375, a potential best-in-class oral and selective KRAS G12D inhibitor.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback